Lantheus' Ablavar imaging agent
This article was originally published in The Gray Sheet
Executive Summary
Lantheus Medical Imaging launches Ablavar injectable magnetic resonance angiography imaging agent Jan. 20 following FDA approval Jan. 11. Ablavar is the first and only contrast imaging agent approved for use with MRA to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease